Healthcare

Inoviq Ltd (ASX:IIQ) emerged as one of the stronger performers on the ASX healthcare sector on Monday, with the stock climbing 27.38% to AUD 0.54. The rally came as investors continued to focus on the company's pipeline of cancer diagnostics and therapeutic programs, with …

Below, we break down the company's core business, the themes that may be driving attention to DXB stock, the state of the biotechnology and clinical development sector, and the watchpoints that could matter for ASX investors. The aim is to provide balanced context on …

Medical technology has produced some of Australia's most successful growth stories, and PolyNovo (ASX:PNV) has consistently ranked among the market's most closely watched medtech names. The company has built its reputation around NovoSorb, a proprietary regenerative wound-care platform that has gained increasing acceptance in …

Racura Oncology operates in the biotechnology sector, developing therapies or health technologies aimed at addressing unmet medical needs. Biotech companies are typically valued on the potential of their pipeline, the strength of their clinical data, intellectual property, and their pathway towards regulatory approval and …

Mesoblast operates in the biotechnology sector, developing therapies or health technologies aimed at addressing unmet medical needs. Biotech companies are typically valued on the potential of their pipeline, the strength of their clinical data, intellectual property, and their pathway towards regulatory approval and commercialisation. …

Paradigm Biopharmaceuticals operates in the biotechnology sector, developing therapies or health technologies aimed at addressing unmet medical needs. Biotech companies are typically valued on the potential of their pipeline, the strength of their clinical data, intellectual property, and their pathway towards regulatory approval and …

OncoSil Medical operates in the medical technology sector, developing devices, diagnostics or technologies aimed at improving patient care. Medtech companies are typically valued on their products, regulatory approvals, commercialisation progress and the size of the markets they address. Compared with drug development, medical devices …